Peer-reviewed veterinary case report
Lokivetmab – a new option for the treatment and control of canine atopic dermatitis – review
- Journal:
- Clínica Veterinária
- Year:
- 2019
- Authors:
- B. Mascarenhas, Mariana & Bazaga Botelho, Cristiane
- Species:
- dog
Abstract
Monoclonal antibodies have been studied in human medicine for a while. They target specific receptors and cytokines, and are highly specific and effective in blocking their target molecule. Lokivetmab is a monoclonal caninised anti-IL-31 antibody that was recently approved for the treatment of atopic dermatitis in dogs. Currently, no other therapeutic monoclonal antibody is used in veterinary medicine. The goal of this review of literature is to updte clinicians on this new biological option for treatment of canine atopic dermatitis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://doi.org/10.46958/rcv.2019.xxiv.n.141.p.34-38